Metastatic ovarian cancer is cancer that has spread from the ovaries, or the fallopian tubes, to parts of the body outside the site of origin. Ovarian cancer that has metastasized is classified as Stage IV. When cancer is found outside the site of origin — outside the ovary — it may be considered locally advanced … Continued
High-grade serous carcinoma is the most common type of ovarian cancer, accounting for approximately 75% of epithelial ovarian cancers. Because it is the most common type of ovarian cancer, it is often the default type that’s referenced in discussions of ovarian cancer, unless another type is specified. Up until recently, it was thought that ovarian cancers … Continued
Ingrid lives in Denver, Colorado, and was diagnosed with low grade serous ovarian cancer in 2019. What has been your frustration in having a rare form of ovarian cancer? I was diagnosed in January of 2019 with low grade serous ovarian cancer. My doctor said she had to look on Facebook to learn about this … Continued
Sultry summer days can make anyone feel lazy and daydream of faraway places. But at OCRA, we’re working as hard as ever to fulfill our dream of a day when no one need fear an ovarian cancer diagnosis. Check out all that’s happening and discover ways that you can get involved. RESEARCH ADVOCACY PATIENT SUPPORT … Continued
OCRA and the entire ovarian cancer community applaud the action taken on July 13, 2021 by Congresswoman Rosa DeLauro to reauthorize and expand Johanna’s Law. Since it was signed into law in 2007, Johanna’s Law has helped educate and raise awareness of gynecologic cancers to millions of people. Johanna’s Law supports a variety of programs, … Continued
No, ovarian cancer does not stop your period in and of itself. It is still possible to menstruate with the presence of the disease in your body. That being said, let’s answer this question by examining a host of other questions surrounding whether or not ovarian cancer stops one’s period. Can a missed period be … Continued
A study published in the American Journal of Obstetrics & Gynecology provides new insight into previously established research that oral contraceptive use is connected to lower ovarian cancer risk in the general population, by more closely examining the link among BRCA1 and BRCA2 mutation carriers. Scientists have long known that oral contraceptive use, particularly long-term … Continued
Janice lives in NW Pennsylvania, and was diagnosed in 1997, at age 34, with stage II retiform sertoli-leydig cell ovarian cancer with mucinous heterologous elements. What has been your frustration in having a rare form of ovarian cancer? My frustration was getting my rare cell type identified correctly, then finding out the protocol was experimental. Where … Continued
Sally lives in Mechanicsville, VA, and was diagnosed with a granulosa cell tumor. What has been your frustration in having a rare form of ovarian cancer? The most frustrating thing for me is that there is no standard of care and very little research. So little is known about granulosa cell tumor that one of … Continued
Anne lives in Morton, PA, and was diagnosed with small cell carcinoma of the ovary, hypercalcemic type. What has been your frustration in having a rare form of ovarian cancer? My frustration with having a rare form of ovarian cancer is the lack of doctors with knowledge and/or experience in treating women with SCCOHT. I … Continued
Fortuna lives in Naples, Italy, and has adult granulosa cell cancer. What has been your frustration in having a rare form of ovarian cancer? My frustrations were, and are, that there is not a lot of information available about my cancer, and even if you try to share your story with other people with ovarian … Continued
A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors. BRCA1 … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
